Zomiradomide
Zomiradomide is an orally bioavailable PROTAC that induces degradation of IRAK4, IKZF1, and IKZF3. This dual action suppresses NF-κB signaling and activates type I interferon pathways, demonstrating anticancer efficacy in B-cell lymphoma models in preclinical research.
Product Specifications
CAS Number
2655656-99-6
Product Name Alternative
IRAK degrader-1, KT413, KT-413, T75136
Field of Research
Immunology & Inflammation, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.41% (May vary between batches)
Solubility
2% DMSO+40% PEG300+5% Tween 80+53% Saline:3 mg/mL (3.44 mM) ; DMSO:150 mg/mL (172.02 mM)
Smiles
C (N1CC2 (C1) CC (CCNC3=C4C (C (=O) N (C4=O) C5C (=O) NC (=O) CC5) =CC=C3) C2) [C@H]6CC[C@@H] (CC6) C=7SC=8C (N7) =CC (C (C) (C) O) =C (NC (=O) C=9N=C (C (F) (F) F) C=CC9) C8
Molecular Formula
C45H48F3N7O6S
Molecular Weight
871.97
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-61648R-HRP-01 20 µL
Lamin B2 Recombinant Antibody, HRP Conjugated
Sign In for Pricing
View Details